Skip Navigation

Neuro-Oncology 2008 10(4):599-607; doi:10.1215/15228517-2008-029
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Frappaz, D.
Right arrow Articles by Carrie, C.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Frappaz, D.
Right arrow Articles by Carrie, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Society for Neuro-Oncology

Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: Final results of BSG 98 prospective trial

Didier Frappaz, Matthias Schell, Philippe Thiesse, Perrine Marec-Bérard, Carmine Mottolese, David Perol, Christophe Bergeron, Thierry Philip, Anne Claire Ricci, Sophie Galand-Desme, Alexandru Szathmari and Christian Carrie

Pediatric Department, Radiotherapy Department, and Biostatistical Unit, Centre Léon Bérard, Lyon, France (D.F., M.S., P.T., P.M.-B., D.P., C.B., T.P., S.G.-D., C.C.); Pediatric Neurosurgical Unit, Hôpital Pierre Wertheimer, Lyon, France (C.M., A.C.R., A.S.)

Address correspondence to Didier Frappaz, Pediatric Department, Centre Léon Bérard, 28 Rue Laënnec, 69373 Lyon Cedex 08, France (frappaz{at}lyon.fnclcc.fr).


   Abstract

Radiation therapy remains the only treatment that provides clinical benefit to children with diffuse brainstem tumors. Their median survival, however, rarely exceeds 9 months. The authors report a prospective trial of frontline chemotherapy aimed at delaying radiation until time of clinical progression. The aim was to investigate the possibility that radiotherapy would maintain its activity in children whose disease progressed after chemotherapy. Twenty-three patients took part in this protocol, the BSG 98 protocol, which consisted of frontline chemotherapy alternating hematotoxic and nonhematotoxic schedules. Each cycle included three courses delivered monthly; the first course was 1,3-bis(2-chloroethyl)-1-nitrosoureacisplatin, and the second and third were high-dose methotrexate. Three patients underwent one cycle; 5 patients each, two and three cycles; and 10 patients, four cycles. Twenty of the 23 patients eventually received local radiation therapy. A historical cohort of 14 patients who received at least local radiation therapy served as controls. Four patients experienced severe iatrogenic infections, and 11 patients required platelet transfusions. Median survival increased significantly in patients participating in the protocol compared to that in the historical controls (17 months, 95% confidence interval [CI], 10-23 months, vs. 9 months, 95% CI, 8-10 months; p = 0.022), though hospitalization was prolonged (57 vs. 25 days, p = 0.001). Although frontline chemotherapy alternating hematotoxic and nonhematotoxic schedules significantly increases overall median survival, its cost from infection and hospitalization deserves honest discussion with the children and their parents.

Keywords: brainstem, chemotherapy, glioma, radiotherapy

Received December 29, 2006; Accepted February 25, 2008


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Neurol. Neurosurg. PsychiatryHome page
W Rachinger, S Grau, M Holtmannspotter, J Herms, J-C Tonn, and F W Kreth
Serial stereotactic biopsy of brainstem lesions in adults improves diagnostic accuracy compared with MRI only
J. Neurol. Neurosurg. Psychiatry, October 1, 2009; 80(10): 1134 - 1139.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.